Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that the company will be participating in the Rodman & Renshaw 13th Annual Global Investment Conference being held at the Waldorf-Astoria Hotel in New York City from September 11th – 13th. Edward J. Quilty, Chairman and CEO, will deliver the Company’s corporate presentation on Monday, September 12th, at 10:00 a.m. (Eastern Time).

The presentation will be webcast live at and on the Investor Relations section of the Company’s website at, where it will also be archived for 90 days.

Derma Sciences is a medical technology company focused on the wound care marketplace, addressing; traditional dressings, advanced wound care dressings, and pharmaceutical wound care products. Its MEDIHONEY product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB for better management of wound exudate, and BIOGUARD for infection prevention. Derma Sciences has successfully completed a Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, a novel pharmaceutical drug under development for accelerated wound healing and scar reduction.

For more information please visit

Copyright Business Wire 2010